PA
ACRS icon

Perceptive Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Perceptive Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-500,000
Closed -$1.45M – 102
2023
Q3 		$1.45M Buy
+500,000
New +$4.27M 0.05% 86

Other funds holding ACRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Perceptive Advisors's ACRS Position: Q1 2023 in Review

Perceptive Advisors sold out of Aclaris Therapeutics (ACRS) in Q1 2023, closing a stake of 341,239 shares — an estimated $5.37M sold.

Perceptive Advisors first reported a position in ACRS in Q3 2016 and held it in 11 quarters. The position peaked at $37.6M in Q1 2017. 148 funds tracked by Wall St. Rank hold ACRS as of Q1 2023.

  • Perceptive Advisors reported no remaining Aclaris Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Perceptive Advisors sold 341,239 Aclaris Therapeutics shares in Q1 2023, an estimated $5.37M.
  • Perceptive Advisors first reported a position in Aclaris Therapeutics in Q3 2016 and held it in 11 quarters.
  • Perceptive Advisors's Aclaris Therapeutics position peaked at $37.6M in Q1 2017.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2023.

Based on Perceptive Advisors's 13F filing for Q1 2023, filed 15 May 2023.